Neurofibromatosis clinical trials at UCSF
5 in progress, 3 open to eligible people
Neurofibromatosis is a disorder that leads to tumor growth on nerves. UCSF is exploring the effects of trametinib and azacitidine in children with leukemia. Another trial is testing whether selumetinib is as effective as standard treatments for brain tumors in kids. UCSF is also investigating genetic factors in skin tumors for adults with neurofibromatosis type 1.
Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
open to eligible people ages 1 month to 21 years
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML…
San Francisco, California and other locations
Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
open to eligible people ages 2-21
This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in…
San Francisco, California and other locations
Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults with Neurofibromatosis Type 1
open to eligible people ages 40 years and up
The main goal of this protocol is to develop a well-phenotyped genetic biobank to identify genetic variants associated with the heterogeneous clinical presentations of Neurofibromatosis Type 1 (NF1). This will allow for improve understanding of NF1…
Redwood City, California and other locations
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Sorry, in progress, not accepting new patients
This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory).…
San Francisco, California and other locations
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Sorry, in progress, not accepting new patients
This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Trametinib may stop the growth of tumor cells by blocking…
San Francisco, California and other locations
Our lead scientists for Neurofibromatosis research studies include Alyssa T. Reddy.
Last updated: